Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Actuate Therapeutics, Inc. Common stock

A biopharmaceutical company developing treatments for hard-to-treat cancers, aiming to give patients the opportunity to live longer and better through a self-described best-in-class agent.

ACTU

COM:ACTUATETHERAPEUTICS

Actuate Therapeutics

Last Close

8.98

22/11 21:00

Market Cap

195.32M

Beta: -

Volume Today

30.74K

Avg: -

Financials Not Available